Division of Respiratory Medicine, Saiseikai Kumamoto Hospital, 5-3-1 Chikami Minami-ku, Kumamoto city, Kumamoto, 861-4193, Japan.
Crit Care. 2017 Jun 8;21(1):135. doi: 10.1186/s13054-017-1723-0.
The efficacy of corticosteroid use in acute respiratory distress syndrome (ARDS) remains controversial. Generally, short-term high-dose corticosteroid therapy is considered to be ineffective in ARDS. On the other hand, low-dose, long-term use of corticosteroids has been reported to be effective since they provide continued inhibition of the systemic inflammatory response syndrome (SIRS) that accompanies ARDS. Thus far, no reports have been published on the efficacy of initiating treatment with a high-dose corticosteroid regimen with tapering.
We conducted a retrospective observational study involving 186 patients treated at a teaching hospital (68% had sepsis, pneumonia, or aspiration pneumonia). ARDS was diagnosed according to the Berlin definition. Patients were divided into a high-dose (n = 21) or low-dose corticosteroid group (n = 165) to compare the effectiveness of a down-titration regimen. The primary medical team chose which treatment a patient would receive. We were careful to conduct a differential diagnosis of interstitial pneumonia (e.g., acute eosinophilic pneumonia) since corticosteroid treatment has been proven effective in that patient population. The primary outcome was the 60-day mortality rate. The secondary outcome was the number of ventilator-free days (VFD).
Those started on a high-dose regimen had a significantly higher 60-day mortality rate (P = 0.031) with significantly fewer VFD (P = 0.021). Propensity scores were used to adjust patient backgrounds in a variable analysis that also showed the high-dose regimen was a factor in decreasing VFD (OR, 95.63; 95% CI, 1.74-5271.07; P = 0.026) and worsening the 60-day mortality rate (OR, 2.54; 95% CI, 0.92-7.02; P = 0.072).
A tapering regimen after high-dose corticosteroids is likely to increase ventilator dependency and might aggravate the prognosis of patients with ARDS diagnosed according to the Berlin definition.
皮质类固醇在急性呼吸窘迫综合征(ARDS)中的疗效仍存在争议。一般认为,短期大剂量皮质类固醇治疗对 ARDS 无效。另一方面,低剂量、长期使用皮质类固醇被报道是有效的,因为它们可以持续抑制伴随 ARDS 的全身炎症反应综合征(SIRS)。迄今为止,尚无关于起始高剂量皮质类固醇方案逐渐减量治疗的疗效的报告。
我们进行了一项回顾性观察性研究,涉及一家教学医院的 186 名患者(68%患有脓毒症、肺炎或吸入性肺炎)。根据柏林定义诊断为 ARDS。将患者分为高剂量(n=21)或低剂量皮质类固醇组(n=165),以比较逐渐减量方案的疗效。主要医疗团队选择患者接受哪种治疗。我们小心地对间质性肺炎(例如急性嗜酸性肺炎)进行鉴别诊断,因为皮质类固醇治疗已被证明对该患者群体有效。主要结局是 60 天死亡率。次要结局是无呼吸机天数(VFD)。
开始使用高剂量方案的患者 60 天死亡率显著更高(P=0.031),VFD 显著更少(P=0.021)。使用倾向评分在变量分析中调整患者背景,该分析还表明高剂量方案是降低 VFD(OR,95.63;95%CI,1.74-5271.07;P=0.026)和恶化 60 天死亡率(OR,2.54;95%CI,0.92-7.02;P=0.072)的因素。
根据柏林定义诊断的 ARDS 患者使用高剂量皮质类固醇后逐渐减量可能会增加呼吸机依赖,并可能加重预后。